Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Median change of circulating biomarkers.

From: A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer

    Baseline Six weeks Change   
Variable Treat. N Obs Median
IQR
Median
IQR
Median
IQR
Contrast1 P
Fibrinogen P 25 312.0
(273.0 to 340.0)
333.5
(276.0 to 354.0)
4.5
(-19.0 to 24.0)
T vs. R 0.02
mg/dL R 50 301.0
(254.0 to 334.0)
260.0
(230.0 to 288.0)
-29.5
(-61.0 to -5.0)
T + R vs. P 0.01
  T 50 286.0
(247.0 to 319.0)
285.0
(243.0 to 312.0)
-2.0
(-20.0 to 12.0)
  
Antithrombin P 25 102.0
(98.0 to 109.0)
99.0
(93.0 to 104.0)
-1.0
(-5.0 to 4.0)
T vs. R 0.75
% R 50 103.0
(98.0 to 108.0)
94.0
(90.0 to 101.0)
-8.0
(-11.0 to -1.0
T + R vs. P 0.02
  T 50 106.0
(98.0 to 114.0)
100.0
(92.0 to 106.0)
-7.0
(-16.0 to -1.0)
  
CRP P 25 0.6
(0.3 to 2.8)
0.8
(0.3 to 3.3)
0.0
(-0.1 to 0.6)
T vs. R 0.12
mg/dL R 50 1.0
(0.5 to 1.9)
0.6
(0.4 to 1.3)
-0.3
(-0.7 to 0.1)
T + R vs. P 0.21
  T 50 0.7
(0.4 to1.2)
0.8
(0.4 to 1.3)
0.1
(-0.3 to 0.3)
  
Cholesterol P 25 199.0
(185.0 to 224.0)
225.5
(197.0 to 244.0)
13.5
(1.0 to 33.0)
T vs. R 0.30
mg/dL R 50 199.5
(179.0 to 222.0)
192.0
(168.0 to 215.0)
-7.0
(-23.0 to 5.0)
T + R vs. P <.0001
  T 50 201.5
(180.0 to 220.0)
188.5
(171.0 to 200.0)
-12.0
(-18.0 to 0.0)
  
CTX ng/mL P 25 0.3
(0.2 to 0.4)
0.3
(0.2 to 0.3)
0.0
(-0.1 to 0.0)
T vs. R 0.05
  R 50 0.3
(0.2 to 0.4)
0.3
(0.2 to 0.4)
0.0
(0.0 to 0.1)
T + R vs. P 0.58
  T 50 0.3
(0.2 to 0.4)
0.3
(0.2 to 0.4)
0.0
(-0.1 to 0.0)
  
Osteocalcin P 25 16.9
(13.4 to20.3)
16.5
(13.1 to 22.5)
-0.5
(-1.9 to 2.2)
T vs. R 0.39
ng/mL R 50 17.9
(13.8 to 22.5)
16.8
(13.4 to 20.8)
-1.7
(-3.5 to 1.1)
T + R vs. P 0.32
  T 50 16.0
(61.98 to 165.5)
15.3
(12.5 to 20.2)
-0.7
(-2.0 to 1.0)
  
  1. 1Change adjusted for baseline. CRP, C-reactive protein; CTX, C-telopeptide; IQR, interquartile range; P, placebo; R, raloxifene 60 mg/day; T, tamoxifen 10 mg/week.